These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15340558)

  • 21. [Comparison of antiviral activity between FeIFN-omega and FeIFN-alpha].
    Wang H; Jia X; Yang L; Sun L; Wang H; Liu W
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1556-60. PubMed ID: 19160837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype.
    Krasagakis K; Garbe C; Krüger S; Orfanos CE
    J Invest Dermatol; 1991 Aug; 97(2):364-72. PubMed ID: 1712824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.
    Haagmans BL; Kuiken T; Martina BE; Fouchier RA; Rimmelzwaan GF; van Amerongen G; van Riel D; de Jong T; Itamura S; Chan KH; Tashiro M; Osterhaus AD
    Nat Med; 2004 Mar; 10(3):290-3. PubMed ID: 14981511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons.
    Scagnolari C; Vicenzi E; Bellomi F; Stillitano MG; Pinna D; Poli G; Clementi M; Dianzani F; Antonelli G
    Antivir Ther; 2004 Dec; 9(6):1003-11. PubMed ID: 15651759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On interferon research.
    Hou YD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Sep; 19(3):205-6. PubMed ID: 16267893
    [No Abstract]   [Full Text] [Related]  

  • 26. The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein.
    Spiegel M; Pichlmair A; Mühlberger E; Haller O; Weber F
    J Clin Virol; 2004 Jul; 30(3):211-3. PubMed ID: 15135736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma).
    Zheng B; He ML; Wong KL; Lum CT; Poon LL; Peng Y; Guan Y; Lin MC; Kung HF
    J Interferon Cytokine Res; 2004 Jul; 24(7):388-90. PubMed ID: 15296649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Present state of in vitro and in vivo studies on efficacy of medical nonspecific protective agents with respect to genotype IV coronavirus causing severe acute respiratory syndrome].
    Shchukina VN; Loginova SIa; Borisevich SV; Bondarev VP
    Antibiot Khimioter; 2011; 56(9-10):41-6. PubMed ID: 22586904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid.
    He R; Adonov A; Traykova-Adonova M; Cao J; Cutts T; Grudesky E; Deschambaul Y; Berry J; Drebot M; Li X
    Biochem Biophys Res Commun; 2004 Aug; 320(4):1199-203. PubMed ID: 15249217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recombinant human interferon alpha 2b broad-spectrum anti-respiratory viruses pharmacodynamics study in vitro].
    Wang HQ; Ma LL; Jiang JD; Pang R; Chen YJ; Li YH
    Yao Xue Xue Bao; 2014 Nov; 49(11):1547-53. PubMed ID: 25757280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections.
    Tong TR
    Infect Disord Drug Targets; 2009 Apr; 9(2):223-45. PubMed ID: 19275708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities.
    Ozes ON; Reiter Z; Klein S; Blatt LM; Taylor MW
    J Interferon Res; 1992 Feb; 12(1):55-9. PubMed ID: 1573283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS coronavirus anti-infectives.
    Tong TR
    Recent Pat Antiinfect Drug Discov; 2006 Nov; 1(3):297-308. PubMed ID: 18221155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice.
    Kumaki Y; Day CW; Bailey KW; Wandersee MK; Wong MH; Madsen JR; Madsen JS; Nelson NM; Hoopes JD; Woolcott JD; McLean TZ; Blatt LM; Salazar AM; Smee DF; Barnard DL
    Antivir Chem Chemother; 2010 Mar; 20(4):169-77. PubMed ID: 20231782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helicases as antiviral drug targets.
    Huang JD; Zheng BJ; Sun HZ
    Hong Kong Med J; 2008 Aug; 14 Suppl 4():36-8. PubMed ID: 18708673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase.
    Adedeji AO; Singh K; Calcaterra NE; DeDiego ML; Enjuanes L; Weiss S; Sarafianos SG
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4718-28. PubMed ID: 22733076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins.
    Scagnolari C; Trombetti S; Alberelli A; Cicetti S; Bellarosa D; Longo R; Spanò A; Riva E; Clementi M; Antonelli G
    Intervirology; 2007; 50(2):156-60. PubMed ID: 17191018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS).
    Kesel AJ
    Curr Med Chem; 2005; 12(18):2095-162. PubMed ID: 16101496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.
    Strayer DR; Dickey R; Carter WA
    Infect Disord Drug Targets; 2014; 14(1):37-43. PubMed ID: 25019238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.